These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 22643972)

  • 1. Understanding the molecular mechanism of the broad and potent neutralization of HIV-1 by antibody VRC01 from the perspective of molecular dynamics simulation and binding free energy calculations.
    Zhang Y; Pan D; Shen Y; Jin N; Liu H; Yao X
    J Mol Model; 2012 Sep; 18(9):4517-27. PubMed ID: 22643972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A single residue within the V5 region of HIV-1 envelope facilitates viral escape from the broadly neutralizing monoclonal antibody VRC01.
    Guo D; Shi X; Arledge KC; Song D; Jiang L; Fu L; Gong X; Zhang S; Wang X; Zhang L
    J Biol Chem; 2012 Dec; 287(51):43170-9. PubMed ID: 23100255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01.
    Li Y; O'Dell S; Walker LM; Wu X; Guenaga J; Feng Y; Schmidt SD; McKee K; Louder MK; Ledgerwood JE; Graham BS; Haynes BF; Burton DR; Wyatt RT; Mascola JR
    J Virol; 2011 Sep; 85(17):8954-67. PubMed ID: 21715490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 2-4-Amino Acid Deletion in the V5 Region of HIV-1 Env gp120 Confers Viral Resistance to the Broadly Neutralizing Human Monoclonal Antibody, VRC01.
    Tachibana S; Sasaki M; Tanaka T; Inoue M; Ophinni Y; Kotaki T; Kameoka M
    AIDS Res Hum Retroviruses; 2017 Dec; 33(12):1248-1257. PubMed ID: 28903577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01.
    Zhou T; Georgiev I; Wu X; Yang ZY; Dai K; Finzi A; Kwon YD; Scheid JF; Shi W; Xu L; Yang Y; Zhu J; Nussenzweig MC; Sodroski J; Shapiro L; Nabel GJ; Mascola JR; Kwong PD
    Science; 2010 Aug; 329(5993):811-7. PubMed ID: 20616231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational discovery of novel HIV-1 entry inhibitors based on potent and broad neutralizing antibody VRC01.
    Andrianov AM; Kashyn IA; Tuzikov AV
    J Mol Graph Model; 2015 Sep; 61():262-71. PubMed ID: 26298811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor.
    Kong L; Ju B; Chen Y; He L; Ren L; Liu J; Hong K; Su B; Wang Z; Ozorowski G; Ji X; Hua Y; Chen Y; Deller MC; Hao Y; Feng Y; Garces F; Wilson R; Dai K; O'Dell S; McKee K; Mascola JR; Ward AB; Wyatt RT; Li Y; Wilson IA; Zhu J; Shao Y
    Immunity; 2016 Apr; 44(4):939-50. PubMed ID: 27067056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies.
    Lynch RM; Wong P; Tran L; O'Dell S; Nason MC; Li Y; Wu X; Mascola JR
    J Virol; 2015 Apr; 89(8):4201-13. PubMed ID: 25631091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural basis for germline antibody recognition of HIV-1 immunogens.
    Scharf L; West AP; Sievers SA; Chen C; Jiang S; Gao H; Gray MD; McGuire AT; Scheid JF; Nussenzweig MC; Stamatatos L; Bjorkman PJ
    Elife; 2016 Mar; 5():. PubMed ID: 26997349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.
    Wu X; Wang C; O'Dell S; Li Y; Keele BF; Yang Z; Imamichi H; Doria-Rose N; Hoxie JA; Connors M; Shaw GM; Wyatt RT; Mascola JR
    J Virol; 2012 May; 86(10):5844-56. PubMed ID: 22419808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heavy chain-only IgG2b llama antibody effects near-pan HIV-1 neutralization by recognizing a CD4-induced epitope that includes elements of coreceptor- and CD4-binding sites.
    Acharya P; Luongo TS; Georgiev IS; Matz J; Schmidt SD; Louder MK; Kessler P; Yang Y; McKee K; O'Dell S; Chen L; Baty D; Chames P; Martin L; Mascola JR; Kwong PD
    J Virol; 2013 Sep; 87(18):10173-81. PubMed ID: 23843638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased Epitope Complexity Correlated with Antibody Affinity Maturation and a Novel Binding Mode Revealed by Structures of Rabbit Antibodies against the Third Variable Loop (V3) of HIV-1 gp120.
    Pan R; Qin Y; Banasik M; Lees W; Shepherd AJ; Cho MW; Kong XP
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29343576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N463 Glycosylation Site on V5 Loop of a Mutant gp120 Regulates the Sensitivity of HIV-1 to Neutralizing Monoclonal Antibodies VRC01/03.
    Wang W; Zirkle B; Nie J; Ma J; Gao K; Chen XS; Huang W; Kong W; Wang Y
    J Acquir Immune Defic Syndr; 2015 Jul; 69(3):270-7. PubMed ID: 25751231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viral resistance to VRC01-like antibodies with mutations in loop D and V5 from an HIV-1 B' subtype infected individual with broadly neutralization activity.
    Zhang D; Liu Z; Wang W; Chen MX; Hou JL; Zhang Z; Ren WH; Ren L; Hao YL
    Mol Immunol; 2022 May; 145():50-58. PubMed ID: 35290812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural elements of primary CCR5-using HIV-1 gp120 proteins influencing sensitivity and resistance to the broadly neutralizing monoclonal antibody b12.
    Sterjovski J; Churchill MJ; Ellett A; Wesselingh SL; Ramsland PA; Gorry PR
    Virology; 2012 Oct; 432(2):394-404. PubMed ID: 22818780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
    Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing the potency and breadth of an HIV antibody by using structure-based rational design.
    Diskin R; Scheid JF; Marcovecchio PM; West AP; Klein F; Gao H; Gnanapragasam PN; Abadir A; Seaman MS; Nussenzweig MC; Bjorkman PJ
    Science; 2011 Dec; 334(6060):1289-93. PubMed ID: 22033520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bacterially expressed HIV-1 gp120 outer-domain fragment immunogens with improved stability and affinity for CD4-binding site neutralizing antibodies.
    Rathore U; Purwar M; Vignesh VS; Das R; Kumar AA; Bhattacharyya S; Arendt H; DeStefano J; Wilson A; Parks C; La Branche CC; Montefiori DC; Varadarajan R
    J Biol Chem; 2018 Sep; 293(39):15002-15020. PubMed ID: 30093409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.